Literature DB >> 8815563

Detection of a hypercoagulable state in nonvalvular atrial fibrillation and the effect of anticoagulant therapy.

R Mitusch1, H J Siemens, M Garbe, T Wagner, A Sheikhzadeh, K W Diederich.   

Abstract

The purpose of the study was to evaluate alterations of the hemostatic system and the effect of anticoagulant therapy in nonvalvular atrial fibrillation. A set of molecular hematologic markers was measured prospectively in 69 patients with atrial fibrillation and 28 age-matched patients in sinus rhythm. Significantly elevated levels of thrombin-antithrombin III complex (8.5 +/- 1.6 vs. 2.5 +/- 0.3 micrograms/l; p < 0.001), fibrin monomers (27.1 +/- 3.2 vs. 13.4 +/- 3.7 nM; p < 0.001), D-dimers (788 +/- 76 vs. 405 +/- 46 micrograms/l; p < 0.005), and tissue-type plasminogen activator (9.6 +/- 0.5 vs. 7.2 +/- 0.5 micrograms/l; p < 0.05) were observed in patients with atrial fibrillation compared to those in sinus rhythm. In a subgroup of patients in whom anticoagulant therapy with oral coumadin or standard intravenous heparin was established after the initial study, hemostatic activation decreased significantly. In conclusion, molecular hematologic markers indicate a hypercoagulable state in atrial fibrillation which may characterized a group of patients at elevated risk of thromboembolic disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8815563

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  16 in total

1.  Von Willebrand Factor: Multimeric Structure and Functional Activity in Patients With Atrial Fibrillation With and Without Oral Anticoagulation.

Authors:  Sandra Lopez-Castaneda; Ignacio Valencia-Hernández; Carlos Arean; Daniel Godínez-Hernández; Martha Eva Viveros-Sandoval
Journal:  Clin Appl Thromb Hemost       Date:  2017-06-15       Impact factor: 2.389

Review 2.  Contemporary management of atrial fibrillation: update on anticoagulation and invasive management strategies.

Authors:  Mark A Crandall; David J Bradley; Douglas L Packer; Samuel J Asirvatham
Journal:  Mayo Clin Proc       Date:  2009-07       Impact factor: 7.616

3.  Hypercoagulability and haemodynamic abnormalities in atrial fibrillation.

Authors:  G Y Lip
Journal:  Heart       Date:  1997-05       Impact factor: 5.994

4.  Nonvalvular atrial fibrillation: evidence for a prothrombotic state.

Authors:  S R Kahn; S Solymoss; K M Flegel
Journal:  CMAJ       Date:  1997-09-15       Impact factor: 8.262

5.  Soluble Fibrin Monomer Complex and Prediction of Cardiovascular Events in Atrial Fibrillation: The Observational Murcia Atrial Fibrillation Project.

Authors:  José Miguel Rivera-Caravaca; Vanessa Roldán; Marta Romera; María Asunción Esteve-Pastor; Mariano Valdés; Gregory Y H Lip; Vicente Vicente; Francisco Marín
Journal:  J Gen Intern Med       Date:  2018-03-22       Impact factor: 5.128

Review 6.  Biomarkers in atrial fibrillation: investigating biologic plausibility, cause, and effect.

Authors:  Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2005-02       Impact factor: 2.300

7.  Impaired fibrinolytic capacity in rheumatic mitral stenosis with or without atrial fibrillation and nonrheumatic atrial fibrillation.

Authors:  Enver Atalar; Ferhan Ozmen; Ibrahim Haznedaroğlu; Necla Ozer; Serdar Aksöyek; Kenan Ovünç; Nasih Nazli; Serafettin Kirazli; Sirri Kes
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 8.  Mechanisms And Management Of Thrombo-Embolism In Atrial Fibrillation.

Authors:  Francesco Violi; Daniele Pastori; Pasquale Pignatelli
Journal:  J Atr Fibrillation       Date:  2014-10-31

9.  Association of hemostatic markers with atrial fibrillation: a meta-analysis and meta-regression.

Authors:  Na Wu; Shifei Tong; Ying Xiang; Long Wu; Bin Xu; Yao Zhang; Xiangyu Ma; Yafei Li; Zhiyuan Song; Li Zhong
Journal:  PLoS One       Date:  2015-04-17       Impact factor: 3.240

10.  The role of soluble fibrin during anticoagulant therapy: a case report.

Authors:  Tohru Kawakami; Nobukiyo Tanaka; Hiroki Ishihara; Hiroyoshi Ohno
Journal:  Thromb J       Date:  2015-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.